Calfa, C. J., Rothe, M., Srkalovic, G., Duvivier, H. L., Behl, D., Straughn, J. M., … Schilsky, R. L. (2023). Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Calfa, Carmen Julia, Michael Rothe, Gordan Srkalovic, Herbert Leon Duvivier, Deepti Behl, J Michael Straughn, Kathleen J. Yost, et al. “Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Calfa CJ, Rothe M, Srkalovic G, Duvivier HL, Behl D, Straughn JM, et al. Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Calfa, Carmen Julia, et al. “Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Calfa CJ, Rothe M, Srkalovic G, Duvivier HL, Behl D, Straughn JM, Yost KJ, Mehmi I, Pisick EP, Sharma BB, Thota R, Veljovich DS, Alese OB, Cannon TL, Gaba AG, Urba WJ, von Mehren M, Grantham GN, Halabi S, Schilsky RL. Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2023.